NICE recommends apixaban but rejects roflumilast

New recommendations from the national body have been released regarding Eliquis and Daxas.

Eliquis is recommended by NICE for prevention of venous thromboembolism following hip replacement surgery | SCIENCE PHOTO LIBRARY
Eliquis is recommended by NICE for prevention of venous thromboembolism following hip replacement surgery | SCIENCE PHOTO LIBRARY

Eliquis approved

The National Institute for Health and Care Excellence (NICE) has recommended that apixaban (Eliquis) be made available on the NHS for the prevention of venous thromboembolism in adults after elective hip or knee replacement surgery.

The recommended dosage of apixaban is 2.5mg twice daily. The initial dose should be taken 12–24 hours after surgery. Treatment should be continued for 32–38 days following hip surgery or for 10–14 days following knee surgery.

Daxas rejected    

NICE rejected the use of roflumilast (Daxas) for the management of severe chronic obstructive pulmonary disease (COPD). The PDE4 inhibitor is recommended only as part of a clinical study for adults with severe COPD associated with chronic bronchitis with a history of frequent exacerbations, as an add-on to bronchodilator treatment.  

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

New antibiotic prescribing guidance issued for pneumonia

New antibiotic prescribing guidance issued for pneumonia

NICE has published antimicrobial prescribing guidelines...

MIMS summary of NICE COPD guidance updated

MIMS summary of NICE COPD guidance updated

Prescribers can now consult the quick-reference MIMS...

Soft-mist inhaler now available as reusable device

Soft-mist inhaler now available as reusable device

Respimat is now available as a reusable inhaler that...

NICE recommends 'innovative' treatment for type I diabetes

NICE recommends 'innovative' treatment for type I diabetes

Dapagliflozin (Forxiga) has been approved for routine...